A detailed history of Harbor Investment Advisory, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Harbor Investment Advisory, LLC holds 1,800 shares of NTLA stock, worth $21,924. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,800
Previous 1,800 -0.0%
Holding current value
$21,924
Previous $40,000 10.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 12, 2024

SELL
$23.82 - $32.8 $4,764 - $6,559
-200 Reduced 10.0%
1,800 $49,000
Q3 2023

Oct 13, 2023

SELL
$31.62 - $45.78 $632 - $915
-20 Reduced 0.99%
2,000 $63,000
Q1 2023

Apr 21, 2023

SELL
$33.3 - $44.82 $26,639 - $35,856
-800 Reduced 28.37%
2,020 $75,000
Q4 2022

Jan 24, 2023

SELL
$33.21 - $62.69 $13,284 - $25,076
-400 Reduced 12.42%
2,820 $0
Q3 2022

Nov 01, 2022

BUY
$53.92 - $71.7 $16,176 - $21,510
300 Added 10.27%
3,220 $180,000
Q1 2022

Apr 20, 2022

SELL
$58.27 - $118.99 $113,626 - $232,030
-1,950 Reduced 40.04%
2,920 $212,000
Q4 2021

Jan 10, 2022

SELL
$100.76 - $138.36 $155,170 - $213,074
-1,540 Reduced 24.02%
4,870 $576,000
Q3 2021

Oct 12, 2021

BUY
$132.37 - $176.78 $689,647 - $921,023
5,210 Added 434.17%
6,410 $860,000
Q2 2021

Jul 27, 2021

BUY
$60.88 - $161.91 $54,792 - $145,719
900 Added 300.0%
1,200 $194,000
Q1 2021

Apr 16, 2021

BUY
$46.59 - $83.68 $13,977 - $25,104
300 New
300 $24,000
Q1 2020

May 11, 2020

SELL
$9.44 - $15.58 $4,720 - $7,790
-500 Closed
0 $0
Q4 2019

Jan 16, 2020

BUY
$10.43 - $17.67 $5,215 - $8,835
500 New
500 $7,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Harbor Investment Advisory, LLC Portfolio

Follow Harbor Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbor Investment Advisory, LLC with notifications on news.